Top Ten Most Read Articles in 2024

Blood is pleased to announce the following most read articles that were published in 2024.

1. Management of ALL in adults: 2024 ELN recommendations from a European expert panel
   Experts from the European Leukemia Net (ELN) working group for adult acute lymphoblastic leukemia have identified an unmet need for guidance regarding management of adult acute lymphoblastic leukemia (ALL) from diagnosis to aftercare.


2. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
   Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin lymphoma.


3. How I Treat Anemia in Older Adults
   With the global growing older adult population, clinicians face the common, yet complex challenge of how to evaluate and manage anemia in this population.


4. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel
   Working groups of the European LeukemiaNet have published several important consensus guidelines.


5. How I treat multiple myeloma in geriatric patients
   Multiple myeloma (MM) is primarily a disease of older patients. Until recently, geriatric aspects in the context of MM have been poorly investigated.


6. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
   Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL).


7. PF4 activates the c-Mpl–Jak2 pathway in platelets
   In this study, we show that PF4 binds and activates the thrombopoietin receptor, cellular myeloproliferative leukemia protein (c-Mpl), on platelets.


8. MRD in AML: who, what, when, where, and how?
   Othman et al use retrospective data to show the utility of measurable residual disease (MRD) monitoring of patients with NPM1 acute myeloid leukemia (AML) in de novo treatment using venetoclax-based regimens.


9. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System
   Second primary malignancies were reported in 536 of 12 394 (4.3%) adverse event reports following chimeric antigen receptor T-cell therapies in the Food and Drug Administration Adverse Event Reporting System. Myeloid and T-cell neoplasms were disproportionately more frequently reported, warranting further follow-up.


10. How I treat pediatric venous thromboembolism in the DOAC era
    The direct oral anticoagulants (DOACs) rivaroxaban and dabigatran are newly licensed for the treatment and prevention of venous thromboembolism (VTE) in children and mark a renaissance in pediatric anticoagulation management.